EP3110942A4 - Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu - Google Patents

Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu Download PDF

Info

Publication number: EP3110942A4
Authority: EP; European Patent Office
Prior art keywords: her2; compositions; treatment; methods; expressing tumors
Prior art date: 2014-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP15755609.3A

Other languages

German (de)

English (en)

Other versions

EP3110942A2 (fr

Inventor

Vafa Shahabi

Anu Wallecha

Paulo C. Maciag

Yvonne Paterson

Nicola Mason

Matthew Seavey

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Pennsylvania Penn

Ayala Pharmaceuticals Inc

Original Assignee

University of Pennsylvania Penn

Advaxis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-25

Filing date

2015-02-25

Publication date

2017-08-30

2014-02-25 Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en

2014-05-02 Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en

2015-02-25 Application filed by University of Pennsylvania Penn, Advaxis Inc filed Critical University of Pennsylvania Penn

2017-01-04 Publication of EP3110942A2 publication Critical patent/EP3110942A2/fr

2017-08-30 Publication of EP3110942A4 publication Critical patent/EP3110942A4/fr

Status Withdrawn legal-status Critical Current

Links

101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

EP15755609.3A 2014-02-25 2015-02-25 Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu Withdrawn EP3110942A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US14/189,008 US20150366955A9 (en)	2009-11-11	2014-02-25	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en)	2009-11-11	2014-05-02	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P	2014-11-06	2014-11-06
PCT/US2015/017559 WO2015130810A2 (fr)	2014-02-25	2015-02-25	Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu

Publications (2)

Publication Number	Publication Date
EP3110942A2 EP3110942A2 (fr)	2017-01-04
EP3110942A4 true EP3110942A4 (fr)	2017-08-30

Family

ID=54009773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15755609.3A Withdrawn EP3110942A4 (fr)	2014-02-25	2015-02-25	Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu

Country Status (12)

Country	Link
EP (1)	EP3110942A4 (fr)
JP (1)	JP2017507943A (fr)
KR (2)	KR20240038103A (fr)
CN (1)	CN106661538A (fr)
AU (1)	AU2015223136A1 (fr)
BR (1)	BR112016019534A2 (fr)
CA (1)	CA2940646A1 (fr)
IL (1)	IL247436A0 (fr)
MX (1)	MX2016011114A (fr)
RU (1)	RU2016137834A (fr)
SG (1)	SG11201607036XA (fr)
WO (1)	WO2015130810A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9012141B2 (en)	2000-03-27	2015-04-21	Advaxis, Inc.	Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (fr)	2011-03-11	2012-09-20	John Rothman	Adjuvants a base de listeria
KR20140134695A (ko)	2012-03-12	2014-11-24	어드박시스, 인크.	리스테리아 백신 치료 후 억제 세포 기능 저해
SG11201606677XA (en)	2014-02-18	2016-09-29	Advaxis Inc	Biomarker directed multi-target immunotherapy
MX2016011537A (es) *	2014-03-05	2017-05-01	Advaxis Inc	Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
AU2015250111A1 (en)	2014-04-24	2016-12-08	Advaxis, Inc.	Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr)	2015-03-03	2018-01-09	Advaxis Inc	Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR102883915B1 (ko)	2015-12-16	2025-11-18	시애틀 프로젝트 코포레이션	신생항원 동정, 제조, 및 용도
CA3035591A1 (fr)	2016-11-30	2018-06-07	Advaxis, Inc.	Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
CN111356760A (zh)	2017-09-19	2020-06-30	阿德瓦希斯公司	细菌或李斯特菌菌株的冻干组合物和方法
WO2019075112A1 (fr)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	Identification de néo-antigènes au moyen de points chauds
KR20260008173A (ko)	2017-11-22	2026-01-15	시애틀 프로젝트 코포레이션	신생항원에 대한 접합 에피토프 제시 감소

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120014984A1 (en) *	2009-11-11	2012-01-19	Vafa Shahabi	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6855320B2 (en) *	2000-03-29	2005-02-15	The Trustees Of The University Of Pennsylvania	Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity

2015
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/fr not_active Ceased
- 2015-02-25 CA CA2940646A patent/CA2940646A1/fr active Pending
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/fr not_active Withdrawn
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120014984A1 (en) *	2009-11-11	2012-01-19	Vafa Shahabi	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Also Published As

Publication number	Publication date
JP2017507943A (ja)	2017-03-23
WO2015130810A2 (fr)	2015-09-03
NZ723750A (en)	2024-02-23
IL247436A0 (en)	2016-11-30
EP3110942A2 (fr)	2017-01-04
KR20240038103A (ko)	2024-03-22
BR112016019534A2 (pt)	2017-10-24
SG11201607036XA (en)	2016-09-29
CN106661538A (zh)	2017-05-10
CA2940646A1 (fr)	2015-09-03
WO2015130810A3 (fr)	2016-01-28
RU2016137834A (ru)	2018-03-29
MX2016011114A (es)	2017-02-20
AU2015223136A1 (en)	2016-09-22
KR20160122829A (ko)	2016-10-24

Legal Events

Date	Code	Title	Description
2016-12-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-12-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-01-04	17P	Request for examination filed	Effective date: 20160916
2017-01-04	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-01-04	AX	Request for extension of the european patent	Extension state: BA ME
2017-08-30	A4	Supplementary search report drawn up and despatched	Effective date: 20170801
2017-08-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20170726BHEP Ipc: C12N 1/20 20060101ALI20170726BHEP Ipc: C12N 1/12 20060101AFI20170726BHEP
2018-01-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1232563 Country of ref document: HK
2019-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-02-20	17Q	First examination report despatched	Effective date: 20190117
2019-10-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-11-06	18D	Application deemed to be withdrawn	Effective date: 20190528
2023-09-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1232563 Country of ref document: HK

Publication	Publication Date	Title
HUS2500001I1 (hu)	2025-01-28	Antitestkészítmények daganatkezelésre
EP3092254A4 (fr)	2017-09-20	Composés et compositions pour traiter des tumeurs à her2 positif
ZA201802831B (en)	2021-07-28	Composition for the treatment of igf-1r expressing cancer
IL247436A0 (en)	2016-11-30	Preparations and methods for treating tumors that overexpress her2/neu
EP3936154B8 (fr)	2025-11-05	Compositions et procédés faisant appel à des néo-épitopes cancéreux viraux
EP3399982A4 (fr)	2019-09-18	Associations anti-egfr pour le traitement de tumeurs
EP3166640A4 (fr)	2018-06-13	Compositions de thérapie combinatoire et méthodes de traitement de cancers
EP3148532A4 (fr)	2018-01-03	Association pharmaceutique pour le traitement du cancer
EP3209382A4 (fr)	2018-06-20	Technique d'immunotherapie combinee pour le traitement du cancer
EP3134436A4 (fr)	2017-12-27	Traitement de tumeurs provoquées par h-ras
EP3110443A4 (fr)	2017-11-15	Thérapie combinée pour le traitement du cancer
EP3200815A4 (fr)	2018-04-25	Procédés et compositions pour le traitement du cancer
EP3104880A4 (fr)	2017-10-18	Procédés améliorés pour le traitement de cancers liés à la vascularisation
EP3089992A4 (fr)	2017-07-19	Compositions et méthodes pour l'imagerie du cancer
EP3177308A4 (fr)	2018-04-04	Utilisation de peptides qui bloquent l'interaction métadhérine-snd1 pour le traitement du cancer
EP3139919A4 (fr)	2018-01-10	Composés destinés au traitement du cancer
EP3185910A4 (fr)	2018-01-10	Méthodes et compositions pour le traitement du cancer
EP3548007A4 (fr)	2020-08-12	Méthodes de traitement du cancer
EP3154952A4 (fr)	2018-03-14	Méthodes et compositions pour traiter les cancers her positifs
EP3180011A4 (fr)	2018-03-21	Immunothérapie pour le traitement du cancer
EP3169333A4 (fr)	2018-03-07	Méthodes et compositions pour améliorer un traitement anticancéreux
EP3285763A4 (fr)	2018-12-05	Compositions pour le traitement du cancer
EP3160591A4 (fr)	2018-04-04	Compositions et méthodes pour le traitement du cancer
HK40007662A (en)	2020-06-05	Methods and compositions for cancer therapy
HK1260504A1 (en)	2019-12-20	Compositions and methods for treatment of cancer